| Research Topics: |
| INDEX |
| AI-chat 3 |
| MCS 1 |
| PRIME 28 |
| PRIO 3 |
| aging 7 |
| brain 9 |
| brainwave 1 |
| cancer 8 |
| climate 3 |
| cognition 4 |
| covid-19 2 |
| crime 5 |
| culture 3 |
| dental 1 |
| diabetes 3 |
| drugs 2 |
| economy 2 |
| energy 3 |
| exercise 1 |
| eyes 5 |
| gender 1 |
| genetics 5 |
| gut 1 |
| heart 2 |
| immune 5 |
| language 1 |
| metabolism 1 |
| microbiome 2 |
| nutrition 5 |
| obesity 1 |
| pain 1 |
| physical 1 |
| politics 8 |
| population 6 |
| practice 1 |
| psychology 1 |
| quantum 1 |
| reproduction 1 |
| rights 1 |
| sleep 2 |
| tech 1 |
| vaccine 2 |
| war-confl |
| war-cyber 1 |
|
Scanned: 3298 Evaluated: 234 Selected: 59 Back Issue Map |
| DIABETES DRUGS OBESITY | ||||||||
Mdb42-002 | Linafexor, a Pulsatile FXR Agonist, Augments Low-Dose Semaglutide for Weight Loss in Adults with Obesity, MASH, and Type 2 Diabetes | |||||||
| Quote: | Thus, in a population with blunted GLP-1 responses, adding linafexor to low-dose semaglutide enhanced weight loss and improved body composition and hepatic measures while preserving tolerability--a dose-sparing, mechanism-complementary strategy (ClinicalTrials.gov number, NCT06492330). | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.10.18.26365821v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.10.18.26365821v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Yifei Zhang Yufei Chen Shan Huang Lei Jiang Yufan Wang Jing Ma Rong Deng Juan Du Lili Xia Yuhang Ma Peihong Wu Weituo Zhang Cong Liu Guanguan Zhao Gaihong Wang Mengyi Qian Huimin Lin Fuhua Yan Guang Ning H. Eric Xu Weiqing Wang, | |||||||
| PRIME DRUGS | ||||||||
Sd421-039 | New Drug Reverses Severe Fatty Liver Disease by Repairing the Gut | |||||||
| Quote: | The compound, known as DT-109, works by reducing harmful gut bacteria, protecting the intestinal lining, and preventing inflammatory substances from reaching the liver. According to findings published in The Journal of Clinical Investigation, this approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models, offering a promising new strategy for treating a disease that remains difficult to manage. MASH affects approximately 7 of the worlds population. It is a severe form of fatty liver disease in which excess fat accumulates in the liver, causing inflammation and cellular damage. Over time, the condition can progress to cirrhosis, which involves extensive liver scarring, as well as liver cancer and liver failure. | |||||||
| Article: | https://www.sciencedaily.com//releases/2026/10/261016080912.htm | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| See Also: |
| |||||||
|
Javilk's Research Links Newsletter for Week 42 Updated 10/24/2026-02:39:34 AM Back Issue Topic Map What interests you? What have you found? Tell me! Drop me a note at Javilk.com to subscribe or submit something. |